Natural Product Bioassays
A natural product bioassay is a test that measures the biological effect of an extract, fraction, or pure compound on a living system — cells, enzymes, microbes, or whole organisms. Bioassays are the engine of natural-product discovery: they detect activity, drive the isolation of the responsible compound, and quantify its potency.
Definition
A bioassay is an experimental procedure that determines the presence, concentration, or potency of a biologically active substance by measuring its effect on a living system or biological preparation, expressed through a dose-response relationship.
Scope
The entry covers the role of bioassays in bioactivity-guided isolation, the main assay formats (in vitro target- and cell-based assays and in vivo models), key performance ideas such as dose-response and quantification of potency, and the practical challenges of screening complex natural mixtures. It is a methodological reference, not clinical guidance.
Core questions
- How is biological activity detected in a complex natural extract?
- Which assay format best matches the activity being investigated?
- How is potency quantified and compared across compounds?
- How are artefacts and interfering substances distinguished from genuine activity?
Key concepts
- Bioactivity-guided fractionation
- Dose-response relationship
- IC50 / EC50 potency measures
- Target-based vs phenotypic assays
- High-throughput screening
- Assay interference and false positives
- Synergy and combination effects
Mechanisms
A bioassay exposes a biological system to a test substance across a range of concentrations and records a measurable response, yielding a dose-response curve from which potency (such as IC50 or EC50) is estimated. In natural-product work, bioassays guide fractionation: an active extract is separated and each fraction re-assayed, narrowing down to the pure active constituent. Assay formats range from isolated-enzyme and receptor-binding tests, through cell-based phenotypic assays, to whole-organism models such as zebrafish; methods for analysing combinations quantify whether mixed constituents act additively, synergistically, or antagonistically.
Clinical relevance
Bioassays generate the preclinical activity data that determine whether a natural product advances toward development, and understanding them is part of evaluating natural-product evidence. They describe how activity is measured and validated and are a reference framework, not a basis for individual treatment decisions.
Evidence & guidelines
Bioassay evidence is preclinical and is judged by assay validity, reproducibility, and the use of appropriate controls and dose-response analysis. Reliability depends on counter-screens that rule out interference; results inform, but do not by themselves establish, clinical efficacy.
History
Quantitative bioassay grew from early pharmacology, where the potency of natural extracts such as digitalis was standardised against biological responses. With the rise of natural-product drug discovery, bioactivity-guided fractionation became the standard route from extract to compound, and the field expanded to high-throughput target-based screening and to whole-organism phenotypic models, with combination-analysis methods formalising the study of synergy.
Debates
- Target-based versus phenotypic screening of natural products
- Target-based assays offer mechanistic clarity but may miss compounds acting through unknown mechanisms, whereas phenotypic (cell- or organism-based) assays capture overall activity at the cost of harder target identification; the balance between them is an ongoing methodological discussion.
Key figures
- Gordon M. Cragg
- David J. Newman
- Ting-Chao Chou
- Leonard I. Zon
- Randall T. Peterson
Related topics
Seminal works
- cragg-newman-2005
- zon-peterson-2005
- chou-2006
Frequently asked questions
- What does 'bioactivity-guided fractionation' mean?
- It is the strategy of using a bioassay to track activity while an extract is repeatedly separated into fractions; only the active fractions are carried forward, eventually isolating the pure compound responsible for the effect.
- Why can natural-product extracts give false-positive bioassay results?
- Complex mixtures may contain substances that interfere with the assay readout, aggregate, or non-specifically affect the system, so counter-screens and dose-response confirmation are needed to distinguish genuine activity from artefacts.